Philip W Kantoff

List of Publications by Year in Descending Order

438 papers	52,529 citations	101 h-index	224 g-index
464 ext. papers	60,850 ext. citations	8.2 avg, IF	7.31 L-index

#	Paper	IF	Citations
438	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. *Clinical Cancer Research*, **2021**,	12.9	6
437	Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in -altered Prostate Tumors. *Clinical Cancer Research*, **2021**, 27, 1792-1806	12.9	6
436	Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality. *Cancer*, **2021**, 127, 2623-2630	6.4	0
435	Radiation and androgen deprivation therapy with or without docetaxel in the management of non-metastatic unfavorable-risk prostate cancer: A prospective randomized trial.. *Journal of Clinical Oncology*, **2021**, 39, 5011-5011	2.2	1
434	Provision of subspecialized expert oncology (SEO) opinions using Navya Cancer Data Model (NCDM), a technology-based platform: Prospective study to facilitate access to care.. *Journal of Clinical Oncology*, **2021**, 39, 6580-6580	2.2	
433	Effectiveness of Electroacupuncture or Auricular Acupuncture vs Usual Care for Chronic Musculoskeletal Pain Among Cancer Survivors: The PEACE Randomized Clinical Trial. *JAMA Oncology*, **2021**, 7, 720-727	13.4	14
432	CD38 in Advanced Prostate Cancers. *European Urology*, **2021**, 79, 736-746	10.2	0
431	Inferences About Drug Safety in Phase´III Trials in Oncology: Examples From Advanced Prostate Cancer. *Journal of the National Cancer Institute*, **2021**, 113, 553-561	9.7	2
430	Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells. *Clinical Cancer Research*, **2021**, 27, 2087-2099	12.9	3
429	Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer.. *Journal of Clinical Oncology*, **2021**, 39, 250-250	2.2	
428	Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial. *Journal of Clinical Oncology*, **2021**, 39, 2938-2947	2.2	7
427	Reply to G. Francolini et al. *Journal of Clinical Oncology*, **2021**, 39, 3764-3765	2.2	0
426	Evaluation of an RNAseq-Based Immunogenomic Liquid Biopsy Approach in Early-Stage Prostate Cancer. *Cells*, **2021**, 10,	7.9	1
425	Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. *Clinical Cancer Research*, **2020**, 26, 3230-3238	12.9	49
424	Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer. *Molecular Oncology*, **2020**, 14, 1881-1897	7.9	5
423	Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. *Carcinogenesis* , **2020**, 41, 904-908	4.6	1
422	Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. *Journal of Clinical Oncology*, **2020**, 38, 3032-3041	2.2	13

421	Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1374-1380	4	27
420	Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. *Cancer*, **2020**, 126, 2935-2937	6.4	
419	Patterns of self-reported care in a cohort of prostate cancer survivors: Implications for risk-stratified care. *Journal of Geriatric Oncology*, **2020**, 11, 1164-1167	3.6	1
418	Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 517-526	6.2	48
417	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. *European Urology*, **2020**, 77, 508-547	10.2	155
416	Effects of acupuncture versus cognitive behavioral therapy on cognitive function in cancer survivors with insomnia: A secondary analysis of a randomized clinical trial. *Cancer*, **2020**, 126, 3042-3052	6.4	6
415	Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. *European Urology*, **2020**, 78, 671-679	10.2	37
414	Adverse event profiles of apalutamide, enzalutamide, and darolutamide in SPARTAN, PROSPER, and ARAMIS: How confident are we about which drug is safest?. *Journal of Clinical Oncology*, **2020**, 38, 318-318	2.2	7
413	The effect of abiraterone acetate treatment on CREB and the development of abiraterone acetate resistance in prostate cancer cells.. *Journal of Clinical Oncology*, **2020**, 38, 177-177	2.2	
412	Checkpoint kinase inhibition in prostate cancer cells resistant to poly ADP-ribose polymerase inhibitors.. *Journal of Clinical Oncology*, **2020**, 38, 150-150	2.2	
411	Tumor protein expression of BRCA1 and development of lethal prostate cancer.. *Journal of Clinical Oncology*, **2020**, 38, 65-65	2.2	
410	Fraction genome altered (FGA) to regulate both cell autonomous and non-cell autonomous functions in prostate cancer and its effect on prostate cancer aggressiveness.. *Journal of Clinical Oncology*, **2020**, 38, 347-347	2.2	0
409	A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research. *OncoTargets and Therapy*, **2020**, 13, 13247-13263	4.4	4
408	The impact of the expression of the transcription factor MYBL2 on outcomes of patients with localized and advanced prostate cancer.. *Journal of Clinical Oncology*, **2020**, 38, 149-149	2.2	0
407	Effects of electroacupuncture and auricular acupuncture for chronic pain in cancer survivors: The PEACE randomized controlled trial.. *Journal of Clinical Oncology*, **2020**, 38, 12004-12004	2.2	0
406	Significance of and Co-loss in Aggressive Prostate Cancer Progression. *Clinical Cancer Research*, **2020**, 26, 2047-2064	12.9	32
405	Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. *Clinical Cancer Research*, **2020**, 26, 1086-1093	12.9	10
404	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. *Clinical Cancer Research*, **2020**, 26, 6122-6131	12.9	4

403	Racial Differences in Genomic Profiling of Prostate Cancer. *New England Journal of Medicine*, **2020**, 383, 1083-1085	59.2	28
402	Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation. *Clinical Cancer Research*, **2020**, 26, 5903-5913	12.9	4
401	Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities. *European Urology*, **2020**, 77, 158-166	10.2	21
400	Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer. *International Journal of Cancer*, **2020**, 146, 2694-2702	7.5	0
399	Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. *JCO Precision Oncology*, **2020**, 4, 355-366	3.6	35
398	and COVID-19: Serendipity or Opportunity for Intervention?. *Cancer Discovery*, **2020**, 10, 779-782	24.4	231
397	High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. *Nature Communications*, **2019**, 10, 4358	17.4	50
396	Treatment of Advanced Prostate Cancer. *Annual Review of Medicine*, **2019**, 70, 479-499	17.4	188
395	Time to Prostate-specific Antigen Nadir and the Risk of Death From Prostate Cancer Following Radiation and Androgen Deprivation Therapy. *Urology*, **2019**, 126, 145-151	1.6	4
394	Methylation-associated miR-193b silencing activates master drivers of aggressive prostate cancer. *Molecular Oncology*, **2019**, 13, 1944-1958	7.9	10
393	Genomic correlates of clinical outcome in advanced prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 11428-11436	11.5	383
392	Aneuploidy drives lethal progression in prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 11390-11395	11.5	46
391	Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. *Clinical Cancer Research*, **2019**, 25, 4290-4299	12.9	15
390	A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). *Clinical Cancer Research*, **2019**, 25, 4480-4492	12.9	49
389	Intratumoral Sterol-27-Hydroxylase () Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2019**, 28, 1052-1058	4	9
388	Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications. *European Journal of Cancer*, **2019**, 112, 118-126	7.5	23
387	Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. *Journal of Clinical Oncology*, **2019**, 37, 1051-1061	2.2	104
386	Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival. *Prostate*, **2019**, 79, 73-80	4.2	4

385	Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. *Cancer*, **2019**, 125, 4172-4180	6.4	34
384	Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis.. *Journal of Clinical Oncology*, **2019**, 37, 5035-5035	2.2	4
383	Platinum-based chemotherapy in metastatic prostate cancer with alterations in DNA damage repair genes.. *Journal of Clinical Oncology*, **2019**, 37, 5038-5038	2.2	4
382	PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).. *Journal of Clinical Oncology*, **2019**, 37, TPS5100-TPS5100	2.2	3
381	Targeting checkpoint kinases in prostate cancer cells resistant to poly ADP-ribose polymerase inhibitors.. *Journal of Clinical Oncology*, **2019**, 37, e16543-e16543	2.2	
380	Impact of 5-reductase inhibitor and -blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality. *BJU International*, **2019**, 123, 511-518	5.6	9
379	Treatment of Metastatic Prostate Cancer in 2018. *JAMA Oncology*, **2019**, 5, 263-264	13.4	14
378	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. *JAMA Oncology*, **2019**, 5, 471-478	13.4	257
377	A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. *Cancer*, **2019**, 125, 524-532	6.4	5
376	Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. *Prostate Cancer and Prostatic Diseases*, **2019**, 22, 420-427	6.2	27
375	Low Expression of the Androgen-Induced Tumor Suppressor Gene and Lethal Prostate Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2019**, 28, 707-714	4	9
374	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. *European Urology*, **2019**, 75, 88-99	10.2	216
373	The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. *Journal of Urology*, **2018**, 200, 344-352	2.5	37
372	Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer. *Cancer*, **2018**, 124, 1391-1399	6.4	2
371	Current treatment strategies for advanced prostate cancer. *International Journal of Urology*, **2018**, 25, 220-231	2.3	99
370	Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. *Prostate Cancer and Prostatic Diseases*, **2018**, 21, 364-372	6.2	29
369	Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials. *Cancer*, **2018**, 124, 1383-1390	6.4	3
368	Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). *Prostate*, **2018**, 78, 889-895	4.2	50

367	The long tail of oncogenic drivers in prostate cancer. *Nature Genetics*, **2018**, 50, 645-651	36.3	380
366	Expression of lncRNA MIR222HG co-transcribed from the miR-221/222 gene promoter facilitates the development of castration-resistant prostate cancer. *Oncogenesis*, **2018**, 7, 30	6.6	20
365	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. *European Urology*, **2018**, 73, 178-211	10.2	313
364	Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer. *JAMA Oncology*, **2018**, 4, 558-562	13.4	36
363	Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. *Journal of Pain and Symptom Management*, **2018**, 55, 307-317.e1	4.8	15
362	A Prospective Study of Aspirin Use and Prostate Cancer Risk by Status. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 1231-1233	4	1
361	A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. *Prostate*, **2018**, 78, 1053	4.2	4
360	Regular aspirin use and gene expression profiles in prostate cancer patients. *Cancer Causes and Control*, **2018**, 29, 775-784	2.8	1
359	ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. *Journal of Clinical Investigation*, **2018**, 128, 2979-2995	15.9	31
358	Immunotherapy for biochemically recurrent prostate cancer.. *Journal of Clinical Oncology*, **2018**, 36, 215-215	2.2	5
357	Concurrent deletion of BRCA2 and RB1 and aggressive prostate cancer.. *Journal of Clinical Oncology*, **2018**, 36, 241-241	2.2	
356	Low testosterone at first PSA failure and assessment of the risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.. *Journal of Clinical Oncology*, **2018**, 36, 45-45	2.2	
355	Early versus delayed initiation of salvage androgen deprivation therapy and the risk of prostate cancer-specific mortality.. *Journal of Clinical Oncology*, **2018**, 36, 189-189	2.2	
354	Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in prostate cancer.. *Journal of Clinical Oncology*, **2018**, 36, 240-240	2.2	
353	Regulation of the tumor suppressor PLZF and prostate cancer prognosis.. *Journal of Clinical Oncology*, **2018**, 36, 137-137	2.2	
352	Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry.. *Journal of Clinical Oncology*, **2018**, 36, 203-203	2.2	
351	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. *Journal of Clinical Oncology*, **2018**, 36, 414-424	2.2	107
350	Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. *Nature Biomedical Engineering*, **2018**, 2, 850-864	19	127

349	Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer. *Journal of the Endocrine Society*, **2018**, 2, 485-496	0.4	26
348	Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2018**, 16, 727-734	7.3	1
347	Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncology*, **2017**, 3, 652-658	13.4	34
346	The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies. *Cancer*, **2017**, 123, 1490-1496	6.4	4
345	Neoadjuvant Enzalutamide Prior to Prostatectomy. *Clinical Cancer Research*, **2017**, 23, 2169-2176	12.9	50
344	Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6. *Cancer Research*, **2017**, 77, 753-765	10.1	19
343	The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. *Cancer*, **2017**, 123, 3532-3539	6.4	147
342	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. *JCO Precision Oncology*, **2017**, 2017,	3.6	151
341	Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. *Journal of Clinical Oncology*, **2017**, 35, 3097-3104	2.2	215
340	Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone. *Clinical Genitourinary Cancer*, **2017**,	3.3	18
339	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. *JAMA - Journal of the American Medical Association*, **2017**, 318, 825-835	27.4	235
338	Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. *Cancer*, **2017**, 123, 4130-4138	6.4	8
337	The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. *Prostate*, **2017**, 77, 1303-1311	4.2	11
336	Cancer nanomedicine: progress, challenges and opportunities. *Nature Reviews Cancer*, **2017**, 17, 20-37	31.3	2988
335	Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. *Clinical Cancer Research*, **2017**, 23, 726-734	12.9	77
334	A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. *Clinical Cancer Research*, **2017**, 23, 935-945	12.9	22
333	Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer. *Journal of Clinical Oncology*, **2017**, 35, 124-125	2.2	43
332	Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer. *PLoS ONE*, **2017**, 12, e0184166	3.7	19

331	Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer. *Nature Communications*, **2016**, 7, 10982	17.4	226
330	Gleason score and the risk of cause-specific and all-cause mortality following radiation with or without 6 months of androgen deprivation therapy for men with unfavorable-risk prostate cancer. *Journal of Radiation Oncology*, **2016**, 5, 301-308	0.7	
329	Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 6259-64	11.5	85
328	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. *Clinical Genitourinary Cancer*, **2016**, 14, e299-305	3.2	9
327	Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer. *Journal of Clinical Oncology*, **2016**, 34, 352-9	2.2	28
326	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. *Journal of Clinical Oncology*, **2016**, 34, 1402-18	2.2	666
325	Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. *Clinical Genitourinary Cancer*, **2016**, 14, 352-9	3.3	21
324	Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer--Reply. *JAMA - Journal of the American Medical Association*, **2016**, 315, 1055-6	27.4	2
323	Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. *European Urology*, **2016**, 70, 549-552	10.2	98
322	Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. *JAMA Oncology*, **2016**, 2, 85-93	13.4	61
321	Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer. *Journal of Nuclear Medicine*, **2016**, 57, 46-53	8.9	99
320	IMAAGEN trial safety and efficacy update: Effect of abiraterone acetate and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer.. *Journal of Clinical Oncology*, **2016**, 34, 5061-5061	2.2	6
319	The impact of statin use on abiraterone acetate (AA) treatment duration in patients with castration-resistant prostate cancer (CRPC).. *Journal of Clinical Oncology*, **2016**, 34, 196-196	2.2	1
318	Institutional implementation of clinical tumor profiling on an unselected cancer population. *JCI Insight*, **2016**, 1, e87062	9.9	245
317	A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer. *Prostate*, **2016**, 76, 1338-41	4.2	
316	Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis. *Prostate*, **2016**, 76, 691-9	4.2	15
315	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. *New England Journal of Medicine*, **2016**, 375, 443-53	59.2	791
314	The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. *Cancer & Metabolism*, **2016**, 4, 22	5.4	20

313	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma **2016**, 4, 92		25
312	A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. *Journal of Clinical Oncology*, **2016**, 34, 1913-20	2.2	23
311	Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 1050-1058	4	39
310	Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial. *Journal of Clinical Oncology*, **2016**, 34, 3781-3786	2.2	12
309	Physical and emotional health information needs and preferences of long-term prostate cancer survivors. *Patient Education and Counseling*, **2016**, 99, 2049-2054	3.1	16
308	Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. *Clinical Cancer Research*, **2015**, 21, 3619-30	13.9	96
307	Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. *Journal of Clinical Oncology*, **2015**, 33, 1356-63	2.2	92
306	Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. *Human Genetics*, **2015**, 134, 439-50	6.3	34
305	A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. *Clinical Genitourinary Cancer*, **2015**, 13, 113-23	3.3	32
304	Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. *Journal of Urology*, **2015**, 194, 91-7	2.5	50
303	GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis. *Clinical Genitourinary Cancer*, **2015**, 13, 370-377.e1	3.3	7
302	Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. *JAMA Oncology*, **2015**, 1, 495-504	13.4	87
301	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. *Mayo Clinic Proceedings*, **2015**, 90, 996-1000	6.4	105
300	Androgen deprivation therapy reversibly increases endothelium-dependent vasodilation in men with prostate cancer. *Journal of the American Heart Association*, **2015**, 4,	6	15
299	PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. *Cancer Research*, **2015**, 75, 1944-8	10.1	40
298	The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. *Chemico-Biological Interactions*, **2015**, 234, 332-8	5	49
297	Identifying suicidal symptoms in prostate cancer survivors using brief self-report. *Journal of Cancer Survivorship*, **2015**, 9, 59-67	5.1	12
296	DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. *BMC Cancer*, **2015**, 15, 242	4.8	20

295	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. *Neuro-Oncology*, **2015**, 17, 1344-55	1	39
294	Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. *JAMA - Journal of the American Medical Association*, **2015**, 314, 1291-3	27.4	87
293	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. *New England Journal of Medicine*, **2015**, 373, 1814-23	59.2	762
292	Cabozantinib Inhibits Abiraterone© Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity. *Clinical Cancer Research*, **2015**, 21, 5578-87	12.9	14
291	The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. *Nature Genetics*, **2015**, 47, 1346-51	36.3	226
290	Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. *Molecular Cancer Research*, **2015**, 13, 1431-40	6.6	15
289	Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. *JAMA - Journal of the American Medical Association*, **2015**, 314, 2077-9	27.4	84
288	Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. *Clinical Cancer Research*, **2015**, 21, 1273-80	12.9	129
287	Adverse effects of androgen deprivation therapy and strategies to mitigate them. *European Urology*, **2015**, 67, 825-36	10.2	394
286	Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. *Cancer*, **2015**, 121, 2603-11	6.4	9
285	Integrative clinical genomics of advanced prostate cancer. *Cell*, **2015**, 161, 1215-1228	56.2	1765
284	Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. *Clinical Cancer Research*, **2015**, 21, 2591-600	12.9	119
283	The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). *Journal of the National Cancer Institute*, **2015**, 107, djv261	9.7	35
282	Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less. *Clinical Genitourinary Cancer*, **2015**, 13, e1-6	3.3	15
281	A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer.. *Journal of Clinical Oncology*, **2015**, 33, 274-274	2.2	6
280	Genetic variants of the organic anion transporter SLCO2B1 as pharmacogenomic determinants of response to androgen deprivation therapy (ADT) for prostate cancer.. *Journal of Clinical Oncology*, **2015**, 33, 36-73	2.2	1
279	(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. *American Journal of Nuclear Medicine and Molecular Imaging*, **2015**, 5, 72-82	2.2	15
278	Institutional retrospective review of presurgical cisplatin-based chemotherapy (chemo) in patients with urothelial carcinoma (UC): Gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC).. *Journal of Clinical Oncology*, **2015**, 33, 365-365	2.2	

277	Statin use at the time of initiation of androgen deprivation therapy (ADT) and time to progression (TTP) in patients with hormone-sensitive prostate cancer.. *Journal of Clinical Oncology*, **2015**, 33, 148-148	2.2	
276	Correlation between time to prostate cancer metastasis and overall survival after androgen-deprivation therapy initiation.. *Journal of Clinical Oncology*, **2015**, 33, 250-250	2.2	
275	Association of SLCO transport genes with intraprostatic abiraterone (ABI) levels and pathologic outcomes in men with high-risk localized prostate cancer (PCa).. *Journal of Clinical Oncology*, **2015**, 33, 5013-5013	2.2	1
274	Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. *Nature Biotechnology*, **2014**, 32, 479-84	44.5	434
273	Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. *Nature Medicine*, **2014**, 20, 682-8	50.5	406
272	Elevated IL-8, TNF-□and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. *Prostate*, **2014**, 74, 820-8	4.2	53
271	SPINK1 protein expression and prostate cancer progression. *Clinical Cancer Research*, **2014**, 20, 4904-11	12.9	55
270	Development of Multinuclear Polymeric Nanoparticles as Robust Protein Nanocarriers. *Angewandte Chemie*, **2014**, 126, 9121-9125	3.6	8
269	Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 2027-31	4	21
268	Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. *Integrative Biology (United Kingdom)*, **2014**, 6, 388-98	3.7	43
267	Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. *Journal of Clinical Oncology*, **2014**, 32, 3705-15	2.2	169
266	Development of multinuclear polymeric nanoparticles as robust protein nanocarriers. *Angewandte Chemie - International Edition*, **2014**, 53, 8975-9	16.4	108
265	Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 7319-24	11.5	243
264	Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. *Cancer Discovery*, **2014**, 4, 546-53	24.4	224
263	Prospective enterprise-level molecular genotyping of a cohort of cancer patients. *Journal of Molecular Diagnostics*, **2014**, 16, 660-72	5.1	57
262	Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. *Journal of Clinical Oncology*, **2014**, 32, 1889-94	2.2	177
261	Targeted androgen pathway suppression in localized prostate cancer: a pilot study. *Journal of Clinical Oncology*, **2014**, 32, 229-37	2.2	61
260	Prostate cancer, version 2.2014. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2014**, 12, 686-718	7.3	261

259	Identification of ALK gene alterations in urothelial carcinoma. *PLoS ONE*, **2014**, 9, e103325	3.7	8
258	Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. *Cancer Discovery*, **2014**, 4, 1140-53	24.4	361
257	Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. *Clinical Cancer Research*, **2014**, 20, 1873-83	12.9	38
256	Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer. *Prostate Cancer*, **2014**, 2014, 230812	1.9	10
255	A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T. *Cancer Immunology Research*, **2014**, 2, 988-99	12.5	40
254	Suicidal ideation in prostate cancer survivors: understanding the role of physical and psychological health outcomes. *Cancer*, **2014**, 120, 3393-400	6.4	36
253	FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. *Cancer Medicine*, **2014**, 3, 835-44	4.8	63
252	The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. *Cancer*, **2014**, 120, 1787-93	6.4	34
251	Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. *Prostate*, **2014**, 74, 225-34	4.2	26
250	Population-based patterns of prescription androgen use, 1976-2008. *Pharmacoepidemiology and Drug Safety*, **2014**, 23, 498-506	2.6	17
249	Percent positive biopsy cores and the risk of death from prostate cancer in men with unfavorable-risk prostate cancer. *Journal of Radiation Oncology*, **2014**, 3, 307-312	0.7	
248	Medical Management of Prostate Cancer **2014**, 638-644		
247	Contemporary nationwide patterns of self-reported prostate-specific antigen screening. *JAMA Internal Medicine*, **2014**, 174, 1839-41	11.5	29
246	Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators. *Prostate Cancer*, **2014**, 2014, 912943	1.9	5
245	Effects of a gift certificate incentive and specialized delivery on prostate cancer survivorsO response rate to a mailed survey: a randomized-controlled trial. *Journal of Geriatric Oncology*, **2014**, 5, 127-32	3.6	6
244	Emerging players in prostate cancer: long non-coding RNAs. *American Journal of Clinical and Experimental Urology*, **2014**, 2, 294-9	1.6	11
243	Early detection of prostate cancer: AUA Guideline. *Journal of Urology*, **2013**, 190, 419-26	2.5	721
242	Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. *Annals of Internal Medicine*, **2013**, 158, 853-60	8	87

241	Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. *Urology* , **2013**, 81, 1297-302	1.6	178
240	Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 18638-43	11.5	255
239	Reply to clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. *Cancer*, **2013**, 119, 4053	6.4	1
238	Defining the optimal approach to the patient with postradiation prostate-specific antigen recurrence using outcome data from a prospective randomized trial. *Cancer*, **2013**, 119, 3280-6	6.4	3
237	Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. *Lancet Oncology, The*, **2013**, 14, 81-7	21.7	46
236	Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. *Cancer Immunology, Immunotherapy*, **2013**, 62, 137-47	7.4	198
235	Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. *Urology*, **2013**, 81, 611-6	1.6	9
234	Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. *Nanomedicine*, **2013**, 8, 687-98	5.6	62
233	Punctuated evolution of prostate cancer genomes. *Cell*, **2013**, 153, 666-77	56.2	862
232	Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. *Prostate*, **2013**, 73, 346-54	4.2	189
231	Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. *Journal of the National Cancer Institute*, **2013**, 105, 1881-90	9.7	68
230	Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. *Cancer Journal (Sudbury, Mass)*, **2013**, 19, 50-8	2.2	17
229	A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. *Clinical Cancer Research*, **2013**, 19, 1612-9	12.9	18
228	Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. *Cancer*, **2013**, 119, 2990-8	6.4	26
227	The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). *Cancer*, **2013**, 119, 3636-43	6.4	16
226	New developments in the management of prostate cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2013**, 11, 653-7	7.3	13
225	Associations between single nucleotide polymorphisms (SNPs) in inflammation-related genes and quality of life after radiation therapy (RT) for prostate cancer.. *Journal of Clinical Oncology*, **2013**, 31, 2-2	2.2	
224	Age, comorbidity, and the risk of death in men with PSA failure following radiation therapy.. *Journal of Clinical Oncology*, **2013**, 31, 82-82	2.2	

223	Smoking history and disease outcomes in patients with malignant germ cell tumors.. *Journal of Clinical Oncology*, **2013**, 31, 4561-4561	2.2	
222	The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. *European Urology*, **2012**, 61, 639-47	10.2	24
221	Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade. *BJU International*, **2012**, 110, 1252-6	5.6	4
220	Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. *BJU International* , **2012**, 110, 1729-35	5.6	64
219	EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. *Science*, **2012**, 338, 1465-9	33.3	585
218	Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. *Lancet Oncology, The*, **2012**, 13, 189-95	21.7	61
217	BRAF mutations in metanephric adenoma of the kidney. *European Urology*, **2012**, 62, 917-22	10.2	76
216	Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. *International Journal of Radiation Oncology Biology Physics*, **2012**, 82, 1411-6	4	53
215	Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. *Journal of Urology*, **2012**, 187, 2068-73	2.5	18
214	Integration of immunotherapy into the management of advanced prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2012**, 30, S41-7	2.8	11
213	Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. *Journal of Clinical Oncology*, **2012**, 30, 3020-5	2.2	110
212	The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1497-509	4	230
211	Immunotherapy for castration-resistant prostate cancer. *Urologic Clinics of North America*, **2012**, 39, 465-81	2.9	6
210	A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. *Lancet Oncology, The*, **2012**, 13, 1105-13	21.7	93
209	Low rate of clinician-scored gynecomastia induced by 6 months of combined androgen blockade in a randomized trial: Implications for prophylactic breast irradiation. *Practical Radiation Oncology*, **2012**, 2, 172-178	2.8	1
208	The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. *Prostate*, **2012**, 72, 1093-103	4.2	65
207	Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. *Journal of Clinical Oncology*, **2012**, 30, 1534-40	2.2	379
206	Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. *Nature Genetics*, **2012**, 44, 685-9	36.3	1079

205	Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. *Science Translational Medicine*, **2012**, 4, 128ra39	17.5	866
204	Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. *Cancer*, **2012**, 118, 4777-84	6.4	40
203	Neuroepithelial tumor arising in a testicular teratoma with retroperitoneal metastasis. *Journal of Clinical Oncology*, **2012**, 30, e172-4	2.2	0
202	Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. *Journal of the National Cancer Institute*, **2012**, 104, 1107-9; author reply 1109-12	9.7	30
201	Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 11252-7	11.5	82
200	Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. *Journal of Clinical Oncology*, **2012**, 30, 507-12	2.2	151
199	Prostate-specific antigen test for prostate cancer screening: American Society of Clinical Oncology provisional clinical opinion. *Journal of Oncology Practice*, **2012**, 8, 315-7	3.1	6
198	New agents in metastatic prostate cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2012**, 10, 1403-9	7.3	9
197	Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2012**, 10, 1081-7	7.3	182
196	Use of elevated baseline IL-8, CCL-2, and TNF to predict for shorter overall survival (OS) in men with metastatic prostate cancer initiating androgen-deprivation therapy (ADT).. *Journal of Clinical Oncology*, **2012**, 30, 13-13	2.2	
195	Use of elevated insulin-like growth factor binding protein-1 (IGFBP-1) to predict outcomes in men with metastatic prostate cancer treated with androgen-deprivation therapy (ADT).. *Journal of Clinical Oncology*, **2012**, 30, 191-191	2.2	
194	Recent advances in immunotherapy for the treatment of prostate cancer. *Expert Opinion on Biological Therapy*, **2011**, 11, 997-1009	5.4	15
193	Immunotherapy for the treatment of prostate cancer. *Nature Reviews Clinical Oncology*, **2011**, 8, 551-61	19.4	74
192	Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. *Cancer Prevention Research*, **2011**, 4, 719-28	3.2	38
191	Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. *BJU International*, **2011**, 107, 126-34	5.6	32
190	Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy. *BJU International*, **2011**, 108, 1086-91	5.6	7
189	The genomic complexity of primary human prostate cancer. *Nature*, **2011**, 470, 214-20	50.4	984
188	Secondary hormonal therapy in men with castration-resistant prostate cancer. *Clinical Genitourinary Cancer*, **2011**, 9, 95-103	3.3	13

187	Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients. *Cancer*, **2011**, 117, 517-25	6.4	29
186	Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. *International Journal of Radiation Oncology Biology Physics*, **2011**, 79, 1318-22	4	9
185	Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. *Journal of Clinical Oncology*, **2011**, 29, 2378-85	2.2	96
184	Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. *Journal of Clinical Oncology*, **2011**, 29, 4682-7	2.2	11
183	Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. *Clinical Cancer Research*, **2011**, 17, 1546-52	12.9	15
182	Prostate cancer immunotherapy. *Clinical Cancer Research*, **2011**, 17, 5233-8	12.9	45
181	mRNA expression signature of Gleason grade predicts lethal prostate cancer. *Journal of Clinical Oncology*, **2011**, 29, 2391-6	2.2	119
180	The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. *Cancer Prevention Research*, **2011**, 4, 2044-50	3.2	20
179	Prospective evaluation of analgesic use and risk of renal cell cancer. *Archives of Internal Medicine*, **2011**, 171, 1487-93		51
178	SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. *Journal of Clinical Oncology*, **2011**, 29, 2565-73	2.2	134
177	TREATMENT OF PROSTATE CANCER HORMONAL THERAPY **2011**, 519-557		
176	Immunohistochemical expression of BRCA1 and lethal prostate cancer. *Cancer Research*, **2010**, 70, 3136-9	10.1	96
175	Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. *Journal of Clinical Oncology*, **2010**, 28, 1481-8	2.2	325
174	Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. *Journal of Clinical Oncology*, **2010**, 28, 1099-105	2.2	786
173	Genome-wide association study of prostate cancer mortality. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 2869-76	4	42
172	A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. *Cancer Prevention Research*, **2010**, 3, 604-10	3.2	70
171	Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 1871-8	4	16
170	Changes in PSA kinetics after DNA vaccine therapy-not so fast!. *Journal of Clinical Oncology*, **2010**, 28, e58; author reply e59	2.2	4

169	Reply to L. Le□ et al. *Journal of Clinical Oncology*, **2010**, 28, e417-e417	2.2	
168	Reply to M. Kumar et al. *Journal of Clinical Oncology*, **2010**, 28, e447-e447	2.2	
167	Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. *Clinical Cancer Research*, **2010**, 16, 5244-51	12.9	32
166	Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. *PLoS Genetics*, **2010**, 6, e1001204	6	70
165	Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article. *Journal of Neurosurgery: Spine*, **2010**, 13, 789-94	2.8	30
164	ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation. *Nanomedicine*, **2010**, 5, 361-8	5.6	86
163	Genomic Evaluation and Management of Prostate Cancer **2010**, 477-492		
162	Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *New England Journal of Medicine*, **2010**, 363, 411-22	59.2	3838
161	Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. *BJU International*, **2010**, 105, 1392-6	5.6	20
160	Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. *JAMA - Journal of the American Medical Association*, **2010**, 304, 2373-80	27.4	198
159	NCCN clinical practice guidelines in oncology: prostate cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2010**, 8, 162-200	7.3	555
158	Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. *Cancer*, **2010**, 116, 610-5	6.4	10
157	Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, 337-41	4	14
156	Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. *International Journal of Radiation Oncology Biology Physics*, **2010**, 77, 1046-52	4	38
155	Molecular sampling of prostate cancer: a dilemma for predicting disease progression. *BMC Medical Genomics*, **2010**, 3, 8	3.7	169
154	Cancer of the Genitourinary Tract **2010**, 233-277		
153	Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. *Journal of Clinical Oncology*, **2009**, 27, 3577-83	2.2	61
152	Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence. *Journal of Clinical Oncology*, **2009**, 27, 6000-5	2.2	15

151	Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. *Clinical Cancer Research*, **2009**, 15, 7099-105	12.9	59
150	Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. *Clinical Cancer Research*, **2009**, 15, 3223-30	12.9	44
149	Evaluation of the 8q24 prostate cancer risk locus and MYC expression. *Cancer Research*, **2009**, 69, 5568-74	10.1	102
148	Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. *Clinical Genitourinary Cancer*, **2009**, 7, E90-2	3.3	14
147	Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. *International Journal of Cancer*, **2009**, 125, 1143-6	7.5	9
146	Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. *Cancer*, **2009**, 115, 981-7	6.4	87
145	Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death. *International Journal of Radiation Oncology Biology Physics*, **2009**, 75, 10-5	4	31
144	Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. *Cell*, **2009**, 138, 245-56	56.2	691
143	Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. *Clinical Genitourinary Cancer*, **2009**, 7, 51-7	3.3	20
142	The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. *Cancer Research*, **2009**, 69, 3356-63	10.1	211
141	Screening for prostate cancer. *New England Journal of Medicine*, **2009**, 360, e18	59.2	10
140	Clinical Progression to Castration-Recurrent Prostate Cancer **2009**, 57-72		1
139	Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. *BJU International*, **2008**, 101, 308-12	5.6	37
138	A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. *BJU International*, **2008**, 101, 1084-9	5.6	54
137	Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. *Journal of Urology*, **2008**, 179, 2181-5; discussion 2185-6	2.5	91
136	p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). *Urology*, **2008**, 71, 933-7	1.6	17
135	Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. *Journal of Clinical Oncology*, **2008**, 26, 1148-59	2.2	1651
134	Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. *Journal of Clinical Oncology*, **2008**, 26, 842-7	2.2	86

133	Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. *Cancer Epidemiology Biomarkers and Prevention*, **2008**, 17, 249-51	4	12
132	Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. *Cancer Epidemiology Biomarkers and Prevention*, **2008**, 17, 1682-8	4	17
131	Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. *Journal of the National Cancer Institute*, **2008**, 100, 815-25	9.7	251
130	Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. *Journal of Clinical Oncology*, **2008**, 26, 2979-83	2.2	45
129	Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. *Journal of Clinical Oncology*, **2008**, 26, 2544-9	2.2	147
128	Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. *JAMA - Journal of the American Medical Association*, **2008**, 299, 289-95	27.4	482
127	Does androgen deprivation therapy in men with prostate cancer increase cardiovascular morbidity?. *Nature Reviews Urology*, **2008**, 5, 80-1		1
126	Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes. *Prostate*, **2008**, 68, 839-48	4.2	59
125	Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. *ChemMedChem*, **2008**, 3, 1311-5	3.7	261
124	Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. *Cancer*, **2008**, 112, 1247-53	6.4	91
123	Active surveillance for early-stage prostate cancer: review of the current literature. *Cancer*, **2008**, 112, 1650-9	6.4	220
122	Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. *Cancer*, **2008**, 113, 3290-7	6.4	30
121	Bone directed therapies for prostate cancer. *Journal of Urology*, **2007**, 178, S42-8	2.5	9
120	Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. *Journal of Urology*, **2007**, 177, 2146-50	2.5	22
119	Contemporary trends in low risk prostate cancer: risk assessment and treatment. *Journal of Urology* , **2007**, 178, S14-9	2.5	319
118	Predicting outcomes in prostate cancer: how many more nomograms do we need?. *Journal of Clinical Oncology*, **2007**, 25, 3563-4	2.2	29
117	Genetic determinants of prostate cancer risk. *BJU International*, **2007**, 100, 241-3	5.6	5
116	Prostate-specific antigen screening for prostate cancer: a decision-analytical perspective. *BJU International*, **2007**, 100, 486-8	5.6	2

115	Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. *Nano Letters*, **2007**, 7, 3065-70	11.5	830
114	Advances in the treatment of prostate cancer. *Annual Review of Medicine*, **2007**, 58, 205-20	17.4	27
113	Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. *Journal of Clinical Oncology*, **2007**, 25, 2420-5	2.2	398
112	Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data. *Bioinformatics*, **2007**, 23, 1451-8	7.2	11
111	Aspirin and hormone therapy for prostate cancer. *New England Journal of Medicine*, **2007**, 357, 2737-8	59.2	7
110	Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 2233-6	4	27
109	Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. *Journal of Clinical Oncology*, **2007**, 25, 1038-42	2.2	257
108	Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. *Clinical Cancer Research*, **2007**, 13, 2030-7	12.9	78
107	Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. *Journal of Immunotherapy*, **2007**, 30, 749-61	5	102
106	Development of an integrated prostate cancer research information system. *Clinical Genitourinary Cancer*, **2006**, 5, 61-6	3.3	50
105	Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. *Cancer*, **2006**, 107, 530-5	6.4	40
104	Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. *Cancer*, **2006**, 107, 975-81	6.4	38
103	The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. *Carcinogenesis*, **2006**, 27, 599-605	4.6	29
102	Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. *Journal of Clinical Oncology*, **2006**, 24, 2723-8	2.2	114
101	Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. *Clinical Cancer Research*, **2006**, 12, 152-8	12.9	23
100	Carboplatin for stage I seminoma. *Journal of Clinical Oncology*, **2006**, 24, 2971-2; author reply e32-3	2.2	4
99	Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. *Clinical Genitourinary Cancer*, **2006**, 4, 269-74	3.3	33
98	Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. *Urology*, **2006**, 67, 1235-40	1.6	46

97	Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. *Clinics*, **2006**, 61, 401-8	2.3	30
96	Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 6315-20	11.5	1448
95	Prevention, complementary therapies, and new scientific developments in the field of prostate cancer. *Reviews in Urology*, **2006**, 8 Suppl 2, S9-S14	1	1
94	Autoantibody signatures in prostate cancer. *New England Journal of Medicine*, **2005**, 353, 1224-35	59.2	521
93	Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. *Urology*, **2005**, 66, 386-91	1.6	80
92	Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 1262-9	4	185
91	Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. *BJU International*, **2005**, 96, 783-6	5.6	21
90	The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. *Clinical Cancer Research*, **2005**, 11, 1815-20	12.9	136
89	Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. *Clinical Cancer Research*, **2005**, 11, 5233-40	12.9	151
88	Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy. *Clinical Cancer Research*, **2005**, 11, 5195-8	12.9	12
87	Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 1424-32	4	92
86	p63 regulates commitment to the prostate cell lineage. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 11355-60	11.5	120
85	Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. *Cancer Research*, **2005**, 65, 2498-504	10.1	187
84	Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 1557-61	4	15
83	Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study. *Clinical Cancer Research*, **2005**, 11, 8109-13	12.9	22
82	A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. *Clinical Cancer Research*, **2005**, 11, 284-9	12.9	22
81	Recent progress in management of advanced prostate cancer. *Oncology*, **2005**, 19, 631-6	1.8	11
80	A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. *Clinical Cancer Research*, **2004**, 10, 924-8	12.9	58

79	6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2004**, 292, 821-7	27.4	611
78	Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. *Journal of Clinical Oncology*, **2004**, 22, 3705-12	2.2	99
77	Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. *Journal of Clinical Oncology*, **2004**, 22, 537-56	2.2	167
76	Genotyping and functional analysis of the D104N variant of human endostatin. *Cancer Biology and Therapy*, **2004**, 3, 1298-303	4.6	10
75	Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. *Cancer*, **2004**, 101, 1569-74	6.4	116
74	Effect of finasteride on risk of prostate cancer: how little we really know. *Journal of Cellular Biochemistry*, **2004**, 91, 478-82	4.7	11
73	Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. *Journal of Urology*, **2004**, 171, 709-13	2.5	75
72	Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. *Journal of Urology*, **2004**, 172, S3-5	2.5	4
71	Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. *Clinical Prostate Cancer*, **2004**, 3, 98-103		27
70	Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. *Urology*, **2004**, 63, 327-32	1.6	25
69	Racial differences in screening for prostate cancer in the elderly. *Archives of Internal Medicine*, **2004**, 164, 1858-64		78
68	Opportunities for Targeted Molecular Therapy for Prostate Cancer **2004**, 631-652		
67	Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. *Journal of Clinical Oncology*, **2003**, 21, 490-5	2.2	48
66	The ingredients for prostate cancer nomograms: the addition of biomarkers sets the table for future recipes. *Journal of Clinical Oncology*, **2003**, 21, 3552-3	2.2	4
65	Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 7841-6	11.5	250
64	Chemotherapy for teratoma with malignant transformation. *Journal of Clinical Oncology*, **2003**, 21, 4285-91	2.2	172
63	Time course and predictors of symptoms after primary prostate cancer therapy. *Journal of Clinical Oncology*, **2003**, 21, 3979-86	2.2	181
62	Prevention of prostate cancer with finasteride. *New England Journal of Medicine*, **2003**, 349, 1569-72; author reply 1569-72	59.2	14

61	. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2003**, 26, 312-316	2.7	2
60	Differentiating agents and the treatment of prostate cancer: Vitamin D3 and peroxisome proliferator-activated receptor gamma ligands. *Seminars in Oncology*, **2003**, 30, 698-708	5.5	12
59	Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma. *Cancer*, **2003**, 97, 2171-9	6.4	6
58	Male patients with diagnoses of both breast cancer and prostate cancer. *Breast Journal*, **2003**, 9, 208-12	1.2	15
57	Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. *Journal of Urology*, **2003**, 170, S3-5	2.5	4
56	Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. *Urology*, **2003**, 62, 99-104	1.6	18
55	Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. *Urology*, **2003**, 62, 324-7	1.6	85
54	Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. *Journal of Clinical Oncology*, **2003**, 21, 1232-7	2.2	566
53	Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. *Journal of Clinical Oncology*, **2003**, 21, 2673-8	2.2	306
52	Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. *Cancer Research*, **2003**, 63, 4781-5	10.1	82
51	Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases. *Cancer*, **2002**, 94, 686-9	6.4	12
50	Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. *Cancer*, **2002**, 95, 275-80	6.4	18
49	Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. *Cancer*, **2002**, 95, 1864-8	6.4	43
48	Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer. *Investigational New Drugs*, **2002**, 20, 195-200	4.3	21
47	A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients. *Cancer Investigation*, **2002**, 20, 186-91	2.1	4
46	Changes in body composition during androgen deprivation therapy for prostate cancer. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 599-603	5.6	505
45	ATAAA repeat upstream of glutathione S-transferase P1 and prostate cancer risk. *Urology*, **2002**, 59, 159-64	1.6	4
44	Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. *Urology*, **2002**, 60, 1-6	1.6	24

43	Chemotherapy for prostate cancer. *Urology*, **2002**, 60, 94-100; discussion 100	1.6	99
42	Gene expression correlates of clinical prostate cancer behavior. *Cancer Cell*, **2002**, 1, 203-9	24.3	1829
41	PROGRESSIVE SCLEROSIS OF ISOLATED FOOT METASTASIS OF PROSTATE CANCER. *Journal of Urology*, **2002**, 167, 1392-1392	2.5	5
40	CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. *Cancer Research*, **2002**, 62, 5517-5522	10.1	60
39	Low bone mineral density in hormone-naïve men with prostate carcinoma. *Cancer*, **2001**, 91, 2238-2245	6.4	120
38	Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. *New England Journal of Medicine*, **2001**, 345, 948-55	59.2	593
37	Other novel agents: Rationale and current status as chemopreventive agents. *Urology*, **2001**, 57, 86-9	1.6	13
36	Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. *Urology*, **2001**, 57, 122-6	1.6	54
35	Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. *Journal of Clinical Oncology*, **2001**, 19, 44-53	2.2	158
34	Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. *Journal of Clinical Oncology*, **2001**, 19, 3025-8	2.2	51
33	Low bone mineral density in hormone-naïve men with prostate carcinoma **2001**, 91, 2238		1
32	Amplified in Breast Cancer-1 Glutamine Repeat and Prostate Cancer Risk. *Prostate Journal*, **2000**, 2, 27-32		11
31	HRAS1 Proto-Oncogene Polymorphism and Prostate Cancer. *Prostate Journal*, **2000**, 2, 211-218		
30	Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. *Journal of Clinical Oncology*, **2000**, 18, 3240-6	2.2	42
29	Her-2-neu expression and progression toward androgen independence in human prostate cancer. *Journal of the National Cancer Institute*, **2000**, 92, 1918-25	9.7	288
28	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 1-2000. A 27-year-old man with a painful retroperitoneal mass. *New England Journal of Medicine*, **2000**, 342, 115-22	59.2	3
27	Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma. *Urology*, **2000**, 55, 31-5	1.6	22
26	Treatment of locally advanced prostate cancer: is chemotherapy the next step?. *Journal of Clinical Oncology*, **1999**, 17, 3664-75	2.2	33

25	Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. *Journal of Clinical Oncology*, **1999**, 17, 2506-13	2.2	731
24	Antiandrogens in prostate cancer. *Investigational New Drugs*, **1999**, 17, 271-84	4.3	44
23	Phase II Trial of the Antiestrogen Toremifene for Androgen-Independent Prostate Cancer. *Prostate Journal*, **1999**, 1, 185-189		1
22	A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. *Cancer*, **1999**, 86, 1329-34	6.4	5
21	CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians. *Prostate*, **1999**, 39, 130-4	4.2	45
20	Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. *American Journal of Human Genetics*, **1999**, 64, 1371-7	11	196
19	The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. *Urology*, **1999** , 53, 121-5	1.6	100
18	Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. *Urology*, **1999**, 54, 523-7	1.6	217
17	Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. *Urology*, **1999**, 54, 1064-7	1.6	88
16	Prognostic indicators in hormone refractory prostate cancer. *Urologic Clinics of North America*, **1999** , 26, 303-10, viii	2.9	20
15	MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS. *Journal of Urology*, **1998**, 160, 1220-1229	2.5	205
14	MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER. *Journal of Urology*, **1998**, 1220-1229	2.5	12
13	Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. *Urology*, **1997**, 49, 913-20	1.6	75
12	Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. *Urology*, **1997**, 50, 100-5	1.6	55
11	Constitutive expression of high levels of prostate-specific antigen in the absence of prostate carcinoma. *Urology*, **1996**, 48, 741-6	1.6	7
10	Regulation of S100P expression by androgen. *Prostate*, **1996**, 29, 350-5	4.2	56
9	Nonpalpable Intratesticular Masses Detected Sonographically. *Journal of Urology*, **1995**, 154, 1367-1369	2.5	67
8	Rate of relapse following treatment for localized prostate cancer: a critical analysis of retrospective reports. *International Journal of Radiation Oncology Biology Physics*, **1994**, 28, 303-13	4	17

7	Synchronous adenocarcinoma and transitional cell carcinoma of the bladder associated with augmentation: case report and review of the literature. *Journal of Urology*, **1993**, 149, 115-8	2.5	42
6	Meningeal carcinomatosis from transitional cell carcinoma of the bladder. *Cancer*, **1993**, 72, 553-7	6.4	28
5	Hormonal perturbations in patients with testicular cancer treated with cisplatin. *Cancer*, **1992**, 69, 2306-10	6.4	17
4	Gene therapy: efforts at developing large animal models for autologous bone marrow transplant and gene transfer with retroviral vectors. *Novartis Foundation Symposium*, **1987**, 130, 229-46		1
3	Attempts at gene therapy in beta-thalassemic mice. *Annals of the New York Academy of Sciences*, **1985**, 445, 445-51	6.5	12
2	Histologic demonstration of intradermal spirochetes in a patient with Lyme disease. *American Journal of the Medical Sciences*, **1984**, 287, 40-2	2.2	3
1	Clinical Annotations for Prostate Cancer Research: Defining Data Elements, Creating a Reproducible Analytical Pipeline, and Assessing Data Quality		1